TAURURSODIOL
Neuromuscular Diseases
Amylyx Pharmaceuticals Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Neuromuscular Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Srk-015 Scholar Rock, Inc. | Phase 3 | BB |
Ataluren PTC Therapeutics | Phase 3 | B |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
Taldefgrobep Alfa Biohaven Pharmaceuticals, Inc. | Phase 3 | B |
View all 17 →
Same molecule, other indications
TAURURSODIOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →